Amicus Therapeutics Inc. Stock
Price
Target price
€5.15
€5.15
-
-
-
€16.22
07.07.25 / Frankfurt
WKN: A0MSMZ / Symbol: FOLD / Name: Amicus / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Amicus Therapeutics Inc. Stock
Amicus Therapeutics Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 16 € there is potential for a 210.68% increase which would mean more than doubling the current price of 5.15 € for Amicus Therapeutics Inc..
So far the community has only identified positive things for Amicus Therapeutics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Amicus Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amicus Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc. | - | 7.292% | 0.000% | -43.407% | -43.716% | -52.394% | -62.950% |
| Repligen Corp. | 2.500% | 2.284% | -2.575% | -0.903% | -21.615% | -36.354% | -1.171% |
| Opko Health Inc. | 2.840% | 1.984% | -4.497% | -3.407% | -20.806% | -59.744% | -68.526% |
| Indivior plc | -2.270% | 4.000% | 7.438% | -7.801% | 9.244% | -29.271% | 160.521% |
Comments
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $17.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $21.00 price target on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for FOLD provided by MarketBeat